Pregnant Pause: First Phase III Data Hint At Improved Success For ObsEva IVF Drug
Executive Summary
Top-line data for the IVF drug look promising but what investors really want to see are the Phase III data for ObsEva's lead product expected later this year in the much larger uterine fibroid market.
You may also be interested in...
Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks
Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.
Finance Watch: Is The IPO Boom Making Anyone Nervous Yet?
Public Company Edition: Is the IPO bubble getting ready to burst? It's anybody's guess, but biopharma companies are forging ahead, having launched 11 first-time offerings during the past week and a half. Also, Heron leads recent follow-on offerings with a $200m stock sale to fund what may soon be its third commercial product.
Takeda Paves The Way For Myovant With Phase III Fibroid Success
Takeda has reported the first in a wave of Phase III trials to support the potential uterine fibroid therapy relugolix. The news is good for licensee Myovant, which earlier this year started two larger Phase III studies of the product.